These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 21934116

  • 1. AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection.
    de Lastours V, Pavie J, Delaugerre C, Molina JM.
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(1):9-11. PubMed ID: 21934116
    [Abstract] [Full Text] [Related]

  • 2. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 3. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A, Márquez M, Fernández-Gutiérrez C, Guzmán EP, Brun F, Rodríguez-Iglesias M, Girón-González JA.
    Clin Exp Immunol; 2006 Nov 15; 146(2):270-7. PubMed ID: 17034579
    [Abstract] [Full Text] [Related]

  • 4. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N.
    J Antimicrob Chemother; 2005 Dec 15; 56(6):991-5. PubMed ID: 16308419
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA.
    Clin Infect Dis; 2009 Oct 15; 49(8):e84-91. PubMed ID: 19772388
    [Abstract] [Full Text] [Related]

  • 6. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
    Ronzoni L, Aghemo A, Rumi MG, Prati G, Colancecco A, Porretti L, Monico S, Colombo M, Cappellini MD.
    J Viral Hepat; 2014 Jun 15; 21(6):416-23. PubMed ID: 24750239
    [Abstract] [Full Text] [Related]

  • 7. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W.
    Clin Infect Dis; 2014 Dec 01; 59(11):1579-87. PubMed ID: 25192745
    [Abstract] [Full Text] [Related]

  • 8. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 01; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 9. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.
    Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.
    Aliment Pharmacol Ther; 2013 Jan 15; 37(1):81-90. PubMed ID: 23121150
    [Abstract] [Full Text] [Related]

  • 11. Enhancing the response to interferon-alpha.
    Begemann F, Jablonowski H.
    J Clin Virol; 1999 Jun 15; 13(1-2):1-7. PubMed ID: 10405886
    [Abstract] [Full Text] [Related]

  • 12. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.
    J Infect Chemother; 2014 May 15; 20(5):320-4. PubMed ID: 24477330
    [Abstract] [Full Text] [Related]

  • 13. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
    MMW Fortschr Med; 2004 Apr 26; 146 Spec No 1():74-5. PubMed ID: 15373058
    [No Abstract] [Full Text] [Related]

  • 14. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Taylor LE, Rich JD, Tashima KT.
    N Engl J Med; 2004 Nov 25; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
    [No Abstract] [Full Text] [Related]

  • 15. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
    Keam SJ, Cvetković RS.
    BioDrugs; 2009 Nov 25; 23(1):63-8. PubMed ID: 19344193
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 25; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 17. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.
    Eur J Gastroenterol Hepatol; 2011 Nov 25; 23(12):1192-9. PubMed ID: 21971375
    [Abstract] [Full Text] [Related]

  • 18. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group.
    N Engl J Med; 2004 Jul 29; 351(5):438-50. PubMed ID: 15282351
    [Abstract] [Full Text] [Related]

  • 19. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A, Barrueco N, Esteban Alba C, Escobar Rodríguez I.
    Farm Hosp; 2011 Jul 29; 35(2):93-4. PubMed ID: 20615736
    [No Abstract] [Full Text] [Related]

  • 20. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
    Boesecke C, van Assen S, Stellbrink HJ, Baumgarten A, Ingiliz P, Strassburg CP, Schwarze-Zander C, Wasmuth JC, Hoepelman AI, Rockstroh JK, Arends JE.
    J Viral Hepat; 2014 Nov 29; 21(11):780-5. PubMed ID: 25040149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.